---
layout: default
title: Tezepelumab
parent: Model Prediction Only (L5)
nav_order: 768
evidence_level: L5
indication_count: 10
---

# Tezepelumab
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Tezepelumab: From Severe Asthma to Diabetic Cataract

## One-Sentence Summary

> Tezepelumab is an anti-TSLP monoclonal antibody used clinically for severe asthma (Type 2 inflammatory pathway).
> The TxGNN model predicts it may be effective for **Diabetic Cataract**,
> but this signal is currently supported by **0 clinical trials** and **0 publications**, and the evidence pack's own mechanistic review flags it as a likely false-positive graph-embedding artifact.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Severe Asthma (per drug's known clinical use; not yet confirmed via formal Canada regulatory record) |
| Predicted New Indication | Diabetic Cataract |
| TxGNN Prediction Score | 98.40% |
| Evidence Level | L5 |
| Canada Market Status | ✗ Not Marketed |
| Number of DINs | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in structured form ([Data Gap] flagged as DG002). Based on known information, Tezepelumab is an anti-TSLP (thymic stromal lymphopoietin) monoclonal antibody whose established efficacy is in severe asthma, acting by blocking an upstream epithelial-derived alarmin that drives Type 2 airway inflammation.

The predicted new indication, diabetic cataract, involves an entirely different pathophysiology — lens protein glycation, polyol pathway accumulation, and oxidative stress in the lens epithelium — with no established role for TSLP signaling. The evidence pack's own mechanistic rationale explicitly states that "TSLP and cataract (lens opacification, protein aggregation/oxidative stress mechanisms) have no known biological association, and there is no supporting literature for TSLP expression in aqueous humor or lens epithelium."

Notably, 9 of the top 10 TxGNN predictions for this drug are cataract subtypes (diabetic, tetanic, craniostenosis, immature, mature, nuclear senile, cortical, senile, and diabetes-associated cataract), all clustering at nearly identical scores (~98.2–98.4%). This pattern — a single drug landing on many closely related disease nodes at similar scores, with zero corroborating trials or literature across all of them — is a strong indicator of a knowledge-graph embedding artifact (disease nodes clustering by ontological proximity) rather than a genuine pharmacological signal. Diabetic retinopathy (rank 10) is the only prediction with a partially plausible inflammatory rationale, but even there no TSLP-specific evidence exists.

---

## Clinical Trial Evidence

Currently no related clinical trials registered

---

## Literature Evidence

Currently no related literature available

---

## Canada Market Information

Tezepelumab currently has **0 DINs** registered in Canada (market status: Not Marketed). No product licenses are available to summarize.

---

## Safety Considerations

Please refer to the package insert for safety information.

*(Note: TFDA/Health Canada label warnings and contraindications are flagged as a Blocking data gap — DG001 — and must be resolved before any safety evaluation can proceed.)*

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This is an L5, model-prediction-only signal with zero clinical trials or literature support, and the drug's own mechanistic rationale in the evidence pack explicitly identifies it as biologically implausible (no known TSLP–cataract pathway) and consistent with a graph-embedding clustering artifact rather than a genuine repurposing hypothesis.

**To proceed, the following is needed:**
- Confirmed TFDA/Health Canada product label data (warnings, contraindications) — currently a Blocking gap (DG001)
- Verified mechanism of action data from DrugBank API (DG002)
- Independent mechanistic or preclinical evidence linking TSLP/Th2 inflammation to lens or ocular pathology before any further investment
- Re-evaluation once genuine (non-clustered) clinical or literature evidence emerges, rather than pursuing the current cataract-subtype cluster
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

